R

Regenicin Inc
OTC:RGIN

Watchlist Manager
Regenicin Inc
OTC:RGIN
Watchlist
Price: 0.0003 USD Market Closed
Market Cap: $153

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Regenicin Inc
OTC:RGIN
153 USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
DE
BioNTech SE
NASDAQ:BNTX
28.1B USD
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
22.6B USD
Loading...
DK
Genmab A/S
CSE:GMAB
130.4B DKK
Loading...
US
Incyte Corp
NASDAQ:INCY
19.7B USD
Loading...
US
United Therapeutics Corp
NASDAQ:UTHR
20B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Regenicin Inc
Glance View

Market Cap
153 USD
Industry
N/A

Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The company is headquartered in Little Falls, New Jersey. The company went IPO on 2008-05-12. The firm is focused on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. The firm is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers. Its application are used for treatment of chronic skin wounds.

RGIN Intrinsic Value
Not Available
R
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top